Document is current
Any future updates will be listed below
-
Authors
Qiu, Hai-Bo
Liang, Zhiyan
Yang, Jing
Zhou, Ye
Zhou, Zhi-Wei
Wan, Xiang-Bin
Li, Ning
Tao, Kai-Xiong https://orcid.org/0000-0002-7723-6121
Li, Yong
Wu, Xin
Yang, Chen
Chen, Zi
Wang, Hengbang
Men, Lichuang
Xiong, Yan
Liu, Lihui
Yang, Dajun
Zhai, Yifan
Xu, Rui-Hua https://orcid.org/0000-0001-9771-8534
- License Information
-
More Information
Article History
Received: 28 December 2024
Revised: 26 August 2025
Accepted: 2 October 2025
First Online: 4 November 2025
Competing interests
: Z.L., C.Y., Z.C., H.W., L.M., Y.X., L.L., D.Y., and Y. Zhai are employees of Guangzhou Healthquest Pharma Co., Ltd and/or Ascentage Pharma Group Inc. and hold stock in Ascentage Pharma Group International. D.Y. (leadership role at Ascentage Pharma Group International and Ascentage Pharma Group Inc.) and Y. Zhai (leadership role at Guangzhou Healthquest Pharma Co., Ltd and Ascentage Pharma Group Inc.) are coinventors in the patent application WO 2024/222902 (“Methods of treating TKI-resistant and SDH-deficient GIST” [published and pending]), which is related to this study. All the other authors have no conflicts of interest to declare.
